valu usd unless otherwis note
mix well materi low
expect expect relief ralli
view result given quarter would view
mix given low expect expect revers low
concern around anoth step-down assuag leav
quarter ebitda larg unchang valuat
discount teva combin anticip
near-term gener advair approv introduc much need
leav ebitda littl chang target
model adjust model billion
billion billion billion revenu billion larg
line us/street ep consensu
buysid closer rel street ep higher gross profit
margin lower spend off-set line
guidanc unchang leav wide impli rang
midpoint street three thing
jump north america revenu billion keep
billion quarterli level intact million ep ii
portfolio optimization/restructur sourc margin support
import gener sector theme watch iii gener advair
final stage label review impli near-term approv
updat strateg review anticip strength tomorrow asid
corpor govern part convers order
address perpetu valuat discount closest peer teva
someth call note four issu
need address discount group widen realiti
think likelihood meaning govern chang low
need rais call need take
question continu ask ahead time link
think question go go away clear focu remain
stock consist outperform rate think
under-valued absent ambiti view outlook
increasingli difficult time answer question
trade at/abov teva
mean remov perceiv worst
case buysid expect rang
put near-term catalyst back focu particularli gener
advair ep well restasi exclus unclear
broader group provid favor cross-read
report week us trend stabl
recent stock volatil would suggest still earli continu
see sector stabil approach up-cycl move anticip
consist thesi laid report link
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep ev/ebitda
steadi new gener approv activ low-teen us
gener eros base busi
pipelin approv gener restasi gener
advair risk-adjust
addit accret though assum
addit debt paydown buyback outer year
upsid scenario see valu impli price-to-earnings
upsid ep
view well-posit long-term pipelin
diversifi revenu base learn
last year immun gener industri
pressur manag late capitul react
led steadi downward earn revis
think bottom stronger remain core base
combin emerg complex gener pipelin
posit share upward move follow primari
driver outperform thesi stock
face mani sector headwind
pressur peer given diversif activ
reposit think see growth improv
come year
sever import pipelin catalyst
drive support improv sentiment
long-term growth outlook still appear stabl
increasingli diversifi global footprint import
addit potenti competit epipen gener
copaxon see lower growth peer
risk view three risk view
delay around pipelin convers specif gener
advair restasi impair us base
busi view weaker appreci
risk step-down ebitda contribut
inopportun use cash boost leverag perpetu
inflect higher gener approv activ continu
accret supplement organ growth
portfolio addit debt paydown buyback outer
limit competit high-valu gener greater-
upcom potenti catalyst event focu
gener restasi approv juli bridg goal date
pass approv could come anytim gener advair
receiv potenti quick approv
turnaround addit accret use capit
downsid scenario see valu impli p/
 ep
greater price pressur across us gener portfolio
lead gross margin depress
slowdown ou fail off-set pressur us
failur maintain steadi pipelin convers off-set
exhibit
 incom guid mid teen declin north guid hsd growth eurest guid hsd growth rowoth gener total revenu guid bncost gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi margin guid guid total guid total revenuesoper expens guid net incom pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda use target
multipl result gener valuat framework
taken trough price-to-earnings valuat histor averag valuat made adjust
base company-specif attribut attribut result adjust
lower impli return price target support outperform rate
risk rate price target
risk rate price target includ limit earlier-than-expect
approv key product advair extend delay accret drive
favor accret addit pipelin surpris
lead global gener manufactur base pittsburgh pennsylvania employ
peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
